PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.

@article{Hughes2008PREDICT1T,
  title={PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.},
  author={Sara H Hughes and Arlene R. Hughes and Cindy Brothers and William R. Spreen and Daren E Thorborn},
  journal={Pharmaceutical statistics},
  year={2008},
  volume={7 2},
  pages={121-9}
}
Pharmacogenetics (PGx) - the study of DNA variation in the human genome and the way this impacts the efficacy and safety of medicines - is becoming an increasingly important research tool as physicians, patients, regulatory authorities and payers look for innovative ways to improve the risk:benefit ratio of medicines. While scientific knowledge about PGx is rapidly increasing, implementation of PGx findings to patient care has yet to be fully achieved. One area where significant progress has… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Sequential methods for pharmacogenetic studies

Computational Statistics & Data Analysis • 2012
View 2 Excerpts

Similar Papers

Loading similar papers…